EXTON, PA — dsm-firmenich has appointed Paul Spencer as the new President of its Biomedical business, following an extensive global search conducted by Legacy MEDSearch. Spencer succeeds John Witkowski in the role.
“Paul is a capable leader who possesses strengths that go beyond his industry expertise,” said Philip Eykerman, President of Health, Nutrition & Care at dsm-firmenich. “I have no doubt that our Biomedical business will continue to thrive under his leadership.”
Spencer brings over 30 years of experience in strategy development, leadership, and innovation in healthcare. His background spans advanced drug delivery, implantable medical devices, biomaterials, and excipients.
Paul began his career as a U.S. Army aviation officer before transitioning to sales roles at Biomet, Inc., specializing in craniomaxillofacial and neurosurgery solutions. He later moved into business development for biodegradable biomaterials and parenteral drug delivery.
In 2005, Spencer co-founded Brookwood Pharmaceutical and its subsidiary, Lakeshore Biomaterials. After selling the business to Surmodics, and later to Evonik, he held several leadership roles, ultimately serving as Senior Vice President of Drug Products. He also represented Evonik’s Nutrition and Care Division on the North American Leadership Team.
“I am truly honored and humbled to be the next President of dsm-firmenich Biomedical,” said Spencer. Based in Exton, Pennsylvania, near the Biomedical division’s global headquarters, he looks forward to advancing the company’s mission of bringing progress to life.
Spencer’s appointment marks a new chapter for dsm-firmenich Biomedical, leveraging his extensive experience and strategic vision to drive future growth and innovation.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.